The Gold Standard Protocol

Protocol overview

This is the maximalist protocol: every high-leverage longevity intervention applied together, with the diagnostics to verify it's working. Foundational lifestyle (sleep, Zone 2, resistance training, sauna, Mediterranean diet) is the floor, not the ceiling. On top sits a full RCT-backed supplement stack, the most promising emerging compounds (urolithin A, NMN, quarterly senolytic pulses), advanced diagnostics that change decisions (ApoB, Lp(a), DEXA, VO2 max, CGM, biological age clocks), and — where clinically appropriate and physician-supervised — the modern longevity pharmacology (GLP-1/GIP agonists, low-dose rapamycin, statin/PCSK9 for elevated ApoB). Designed for people with the time, money, and motivation to do everything the evidence currently supports.

Time commitment: 10–14 hours. Complexity: Advanced. Cost level: Premium.

Who this is for

Highly motivated optimizers with the time, budget, and access to a longevity-literate physician needed to execute a comprehensive protocol — and the discipline to track biomarkers and adjust based on what they show.

Core principles

• Lifestyle is the floor: sleep, Zone 2, resistance training, sauna, and a Mediterranean-style whole-food diet are non-negotiable before anything else is added
• Measure what matters quarterly: ApoB, Lp(a), fasting insulin, hs-CRP, HbA1c, omega-3 index, vitamin D, homocysteine — and reassess body composition (DEXA), VO2 max, and grip strength annually
• Use a CGM in 2-week blocks every quarter to identify personal glucose-spiking foods and verify metabolic flexibility
• Build the daily supplement stack on the four RCT-backed essentials (D3+K2, omega-3, magnesium, creatine), then layer the strongest emerging compounds (urolithin A, NMN/NR, GlyNAC) on top
• Senolytic pulses quarterly (fisetin + quercetin phytosome on 2 consecutive days) to allow senescent-cell repopulation between doses
• Treat ApoB aggressively if elevated: statin and/or ezetimibe and/or PCSK9 inhibitors are the highest-leverage cardiovascular intervention available — outperforms any supplement by orders of magnitude
• Consider low-dose rapamycin (typically ~5–6 mg weekly, off-label) and GLP-1 / GIP receptor agonists where indicated, only under physician supervision and with monitoring (CMP, lipids, fasting insulin)
• Annual biological-age clock (TruDiagnostic, GlycanAge, or PhenoAge) to track whether the protocol is actually slowing aging

Interventions from the rankings

• 7-9 hours quality sleep
• 150+ min Zone 2 cardio weekly
• Resistance training 2-3x/week
• Mediterranean diet
• Sauna 4x/week
• Urolithin A (mitochondrial)
• NMN/NR (NAD+ precursors)

Supplement stack

• Omega-3 (High-EPA + High-DHA) — 3–4g combined EPA+DHA daily, split between meals: Foundation: REDUCE-IT (4g EPA, 25% MACE reduction) and ASCEND establish the cardiovascular case; high-DHA fraction drives the neuroprotective benefit. Target an omega-3 index ≥8% on testing.
• Vitamin D3 + K2 (MK-7) — 5,000 IU D3 + 200mcg MK-7 daily, dose-titrated to a 25(OH)D level of 40–60 ng/mL: VITAL trial established cancer-mortality and cardiovascular benefit in deficient populations. K2 (MK-7) directs calcium into bone matrix and out of arterial walls — non-negotiable when D3 dose is high.
• Creatine Monohydrate — 5g daily (some protocols use 0.1–0.2 g/kg in older adults — 8–15g — for stronger sarcopenia/bone effects): The most-studied supplement in existence. Forbes 2022 meta-analysis confirms 1–2kg greater lean mass + meaningful strength gains in older adults; 2023 postmenopausal data supports femoral neck BMD when paired with resistance training. Cognitive benefits are also emerging.
• Magnesium Glycinate + L-Threonate — 300–400mg glycinate at night for systemic + sleep; 1,500–2,000mg L-Threonate AM/midday for brain-targeted Mg: Glycinate covers the systemic deficiency present in ~50% of US adults (BP, sleep, insulin sensitivity). L-Threonate is the only form preclinically shown to raise brain magnesium — small human pilots (Liu 2016, Wroolie 2017) suggest cognitive benefit.
• Urolithin A (Mitopure) — 500–1,000mg daily: The flagship mitophagy compound. Nature Metabolism RCT (2022) showed improved muscle endurance and mitochondrial health markers in middle-aged adults. Strongest mechanism + early human data combo in the emerging-compound space.
• NMN (or NR) + TMG — NMN 500mg or NR 300mg daily AM, paired with TMG 1g to support methylation: Both raise blood NAD+ in human PK studies. RCTs since 2022 (Yoshino, Yamashita, Igarashi, Yi) show modest improvements in muscle insulin sensitivity, endurance, BP, and sleep — effect sizes small but consistent. TMG offsets methyl-group depletion. Note: FDA reclassified NMN out of dietary-supplement status late 2022; product remains widely sold.
• GlyNAC (Glycine + N-Acetyl Cysteine) — Glycine ~100 mg/kg + NAC ~100 mg/kg daily, split between meals: Sekhar lab Baylor RCT (2022, Clinical & Translational Medicine) in older adults: 16 weeks of GlyNAC improved glutathione, insulin resistance, oxidative stress, mitochondrial function, gait speed, and grip strength — among the most impressive multi-system biomarker shifts published for any supplement.
• Fisetin + Quercetin Phytosome (quarterly senolytic pulse) — Fisetin 1,000–1,500mg + Quercetin Phytosome 1,000mg, on 2 consecutive days every 1–3 months (quarterly preferred): Senescent-cell clearance protocol modeled on Mayo Clinic Hickson 2019 (D+Q in IPF) and Justice 2019 (D+Q in diabetic kidney disease). Quarterly pulsing is preferred over monthly per recent Kirkland-lab guidance to allow senescent cells to repopulate between doses.
• Collagen Peptides + Vitamin C — 15g collagen peptides + 50mg vitamin C, 30–60 min pre-workout: Specific RCTs (Shaw 2017, Lis 2020) show pre-exercise collagen + vitamin C doubles collagen synthesis at the tendon — meaningful for joint resilience and injury prevention as training volume increases with age.
• Physician-supervised pharmacology (where clinically appropriate) — Statin / ezetimibe / PCSK9i for ApoB → target <60–80 mg/dL; GLP-1 or GIP/GLP-1 agonist (semaglutide, tirzepatide) for insulin resistance or excess visceral fat; rapamycin ~5–6 mg weekly (off-label, intermittent): These are not supplements — they are the highest-leverage longevity tools available, but require a longevity-literate physician, real prescriptions, and monitoring. SELECT (2023, NEJM): semaglutide cut MACE 20% in non-diabetic adults with obesity + CVD. SURMOUNT-1 (2022): tirzepatide ~22% body-weight reduction. Rapamycin extends median lifespan in every mammalian model tested; human longevity RCTs (PEARL, others) are still ongoing — use only with informed consent and monitoring.

Schedule overview